T1	PROC 46 76	Estudio de fase 3 aleatorizado
T2	PROC 83 128	evaluar la eficacia protectora y la seguridad
T3	CHEM 136 154	vacuna terapéutica
#1	AnnotatorNotes T3	C0042210; Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	DISO 218 221	CMV
#2	AnnotatorNotes T4	C0010823; Cytomegalovirus Infections; Disease or Syndrome
T5	DISO 201 216	citomegalovirus
T6	PROC 235 275	alotrasplante de células hematopoyéticas
T7	PROC 308 315	placebo
#3	AnnotatorNotes T7	C0032042; Placebos; Therapeutic or Preventive Procedure
T8	PROC 322 355	estudio aleatorizado, doble ciego
T9	PROC 379 447	Estudio de fase 3 aleatorizado, doble ciego y controlado con placebo
T10	DISO 571 586	citomegalovirus
T11	PROC 453 498	evaluar la eficacia protectora y la seguridad
T12	CHEM 506 524	vacuna terapéutica
#4	AnnotatorNotes T12	C0042210; Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	DISO 588 591	CMV
#5	AnnotatorNotes T13	C0010823; Cytomegalovirus Infections; Disease or Syndrome
T14	PROC 605 645	alotrasplante de células hematopoyéticas
T15	ANAT 622 645	células hematopoyéticas
#6	AnnotatorNotes T15	C2323499; Hematopoietic cell; Cell
T16	CHEM 156 163	ASP0113
T17	ANAT 252 275	células hematopoyéticas
#7	AnnotatorNotes T17	C2323499; Hematopoietic cell; Cell
T18	CHEM 526 533	ASP0113
T19	Date 13 17	2013
T25	PHYS 260 275	hematopoyéticas
#8	AnnotatorNotes T25	C0018951; Hematopoiesis; Organ or Tissue Function
T27	PHYS 630 645	hematopoyéticas
#9	AnnotatorNotes T27	C0018951; Hematopoiesis; Organ or Tissue Function
#10	AnnotatorNotes T1	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity
#11	AnnotatorNotes T16	C3827159; CMVpp65/gB Plasmid Vaccine ASP0113; Pharmacologic Substance · Immunologic Factor 
#12	AnnotatorNotes T18	C3827159; CMVpp65/gB Plasmid Vaccine ASP0113; Pharmacologic Substance · Immunologic Factor 
#13	AnnotatorNotes T5	C0010823; Cytomegalovirus Infections; Disease or Syndrome
#14	AnnotatorNotes T10	C0010823; Cytomegalovirus Infections; Disease or Syndrome
#15	AnnotatorNotes T8	C0206034; Clinical Trials, Randomized; Research Activity + C0013072; Double-Blind Method; Research Activity
#16	AnnotatorNotes T9	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
T20	LIVB 168 178	receptores
#17	AnnotatorNotes T20	C0376387; Transplant Recipients; Patient or Disabled Group
T21	LIVB 538 548	receptores
#18	AnnotatorNotes T21	C0376387; Transplant Recipients; Patient or Disabled Group
R1	Experiences Arg1:T20 Arg2:T3	
R2	Experiences Arg1:T20 Arg2:T16	
R3	Experiences Arg1:T20 Arg2:T5	
R4	Experiences Arg1:T20 Arg2:T4	
T22	Observation 179 222	seropositivos para el citomegalovirus (CMV)
R6	Experiences Arg1:T20 Arg2:T6	
R9	Experiences Arg1:T20 Arg2:T7	
R10	Experiences Arg1:T20 Arg2:T25	
R11	Experiences Arg1:T21 Arg2:T12	
T23	Observation 549 592	seropositivos para el citomegalovirus (CMV)
R13	Experiences Arg1:T21 Arg2:T18	
R14	Experiences Arg1:T21 Arg2:T10	
R15	Experiences Arg1:T21 Arg2:T13	
R17	Experiences Arg1:T21 Arg2:T14	
R18	Experiences Arg1:T21 Arg2:T27	
R20	Overlap Arg1:T23 Arg2:T10	
R21	Overlap Arg1:T23 Arg2:T13	
R22	Overlap Arg1:T22 Arg2:T5	
R23	Overlap Arg1:T22 Arg2:T4	
R5	Experiences Arg1:T20 Arg2:T22	
R7	Experiences Arg1:T21 Arg2:T23	
#19	AnnotatorNotes T6	C4255274; allogeneic hematopoietic stem cell transplant; Therapeutic or Preventive Procedure
#20	AnnotatorNotes T14	C4255274; allogeneic hematopoietic stem cell transplant; Therapeutic or Preventive Procedure
A1	Experiencer T20 Patient
A2	Experiencer T21 Patient
#21	AnnotatorNotes T22	C2728976; CMV positive liver transplant recipient; Finding
#22	AnnotatorNotes T23	C2728976; CMV positive liver transplant recipient; Finding
